Trial Profile
89Zirconium-labeled pembrolizumab as predictive imaging biomarker of response and toxicity in pembrolizumab treated patients with non-small-cell lung cancer – a feasibility study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Aug 2017
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Diagnostic use
- 24 Jan 2017 New trial record